UNSPSC 51181602: Liothyronine

This classification denotes a generic primary tumor tnm finding with the molecular formula C15H12I3NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 06LU7C9H1V, chemically known as 3,5,3-triiodothyronine but generally known as liothyronine, which bears US NIH Compound Identifier 861. European Medicines Agency schedules Liothyronine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08527MIG.

UNSPSC 51181602 Liothyronine, a Commodity code, represents thyroid hormone replacement medications that state and local health agencies and cooperative purchasing programs procure for distribution through their health systems and facilities. The code encompasses branded and generic liothyronine products supplied to state departments, regional purchasing cooperatives, and subordinate facilities including hospitals, clinics, and public health departments. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is actively soliciting liothyronine and related generic multi-source pharmaceuticals through cooperative purchasing vehicles that serve multiple participating states and local government entities, reflecting the prominence of state-level cooperative purchasing in consolidating pharmaceutical procurement across jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (Solicitation S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed to state and local government facilities across Minnesota, Oregon, and other participating jurisdictions. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and maintain contractual relationships with at least two of the three, with awarded contracts effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent weight), supported by fixed pricing, net price formats (NF30, NF60, NF90), or WAC-minus pricing structures, compliance with cGMP and the Drug Supply Chain Security Act, and EDI capability. Vendors must carry $5,000,000 commercial general liability coverage, $2,000,000 network security and privacy liability, and $2,000,000 professional liability. The contract term runs two years for new vendors with optional extensions, or through June 30, 2028, for incumbent responder amendments. No specific set-aside or disadvantaged-enterprise designations limit responses.